Comparing the current results to its competitors, Prothena Public Limited reported Revenue increase in the 1 quarter 2026 by 1706.36 % year on year. The sales growth was above Prothena Public Limited's competitors' average revenue growth of 15.73 %, achieved in the same quarter.
Prothena Corporation Public Limited Company achieved net profit of $32.72 millions compared to a net loss of $-60.20 millions recorded in the same quarter a year ago.
Prothena Public Limited's Comment on Competition and Industry Peers
The pharmaceutical industry is characterized by intense competition from major international companies with extensive financial resources, technical staff, manufacturing, research and development, and marketing capabilities. The company also faces competition from smaller research firms and manufacturers of generic drugs and biosimilars. Competitive dynamics vary by program and include alternative therapies during periods of patent protection or regulatory exclusivity, followed by generic or biosimilar products thereafter. Government policies promoting the use of generics or biosimilars may impact the growth, sales, and profitability of products lacking patent or exclusivity protection. The introduction of competing products, including generics or biosimilars, can materially affect the company's revenues and operations. The company's competitive position relies on its ability to discover and develop innovative and cost-effective new products. Boehringer Ingelheim Biopharmaceuticals GmbH is identified as the manufacturer of Prasinezumab.
Due to outstanding performance in Overall company, revenue grew by 1706.36 % Prothena Corporation Public Limited Company improved its market share, to approximately 0.06 %.
Publicly Traded Peers of Prothena Corporation Public Limited Company
Enanta Pharmaceuticals Inc Share Performance
+1.59%
Over The Past 5 Days
Enanta Pharmaceuticals Inc
Profile
Enanta Pharmaceuticals Inc's business model focuses on the research, development, and commercialization of innovative small molecule drugs targeting viral infections and liver diseases.
Mineralys Therapeutics Inc is a biotechnology company that follows the business model of developing and commercializing novel therapeutics for various diseases. They focus on discovering and advancing small molecule drugs based on innovative research approaches. Their business model is centered around conducting preclinical and clinical trials, obtaining regulatory approvals, and ultimately bringing their therapeutic products to market for improved patient outcomes.
MannKind Corporation is a biopharmaceutical company that focuses on the development and commercialization of inhaled therapeutic solutions for patients with diseases such as diabetes and pulmonary arterial hypertension. The company's business model revolves around conducting research and development to create innovative inhalation therapies and gaining regulatory approvals for these treatments. They then market and distribute their products, either directly or through partnerships, to healthcare providers and patients worldwide.
Medicinova Inc operates under a biopharmaceutical business model, primarily focused on the development and commercialization of innovative therapeutics. They strive to identify promising drug candidates with the potential to address unmet medical needs and advance them through clinical trials. By leveraging their research capabilities, strategic partnerships, and licensing opportunities, Medicinova Inc aims to bring these novel treatments to market and improve patient outcomes.
Medicure Inc operates as a pharmaceutical company with a business model that focuses on the research, development, and commercialization of innovative cardiovascular and other specialty pharmaceuticals. They aim to address unmet medical needs, improve patient outcomes, and deliver value to healthcare providers and consumers.
Sources:
Prothena Corporation Public Limited Company’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Prothena Corporation Public Limited Company versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
